Showing results (751-760 of 5,983) with videos related to

Sort By:
Pageof 599
Molecular Cancer Therapeutics|October 15, 2008
Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's lymphoma cell linesAzhar R Hussain, Maqbool Ahmed, Naif A Al-Jomah, et al.
Molecular Cancer Therapeutics|October 15, 2008
Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanismSonia Priego, Fatima Feddi, Paula Ferrer, et al.
Molecular Cancer Therapeutics|January 29, 2009
Inhibition of cervical cancer cell growth by human papillomavirus virus-like particles packaged with human papillomavirus oncoprotein short hairpin RNAsLatifa Bousarghin, Antoine Touze, Guillaume Gaud, et al.
Molecular Cancer Therapeutics|January 29, 2009
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell modelsTodd M Pitts, Mark Morrow, Sara A Kaufman, et al.
Molecular Cancer Therapeutics|September 20, 2005
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinomaDemetrius M Kokkinakis, Xiaoyan Liu, Russell D Neuner
Molecular Cancer Therapeutics|September 20, 2005
Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculatureMarina V Backer, Timur I Gaynutdinov, Vimal Patel, et al.
Molecular Cancer Therapeutics|September 16, 2004
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic diseaseSukhdev S Brar, Claude Grigg, Kimberly S Wilson, et al.
Molecular Cancer Therapeutics|September 16, 2004
Structure-based design of a selective heparanase inhibitor as an antimetastatic agentKeisuke Ishida, Go Hirai, Koji Murakami, et al.
Molecular Cancer Therapeutics|September 16, 2004
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activitiesSalvatore DeBonis, Dimitrios A Skoufias, Luc Lebeau, et al.
Molecular Cancer Therapeutics|September 16, 2004
Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutationsManny D Bacolod, Stewart P Johnson, Anthony E Pegg, et al.
Pageof 599